Klinik für Urologie
Thor2
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
Ansprechpartner
Prof. Dr. med. Florian Roghmann
E-Mail: florian.roghmann@
elisabethgruppe.de
Katja Fritz
Gesamtleitung Studienkoordination
Fon: 0 23 02 - 173 -13 27
E-Mail: studienkoordination@
elisabethgruppe.de